DanCann Pharma A/S announces unique results of analysis for its upcoming products. Tetrahydrocannabinol (“THC”) is one of the active substances extracted from cannabis, and DanCann Pharma has succeeded in extracting biomaterial with a solid content of THC. Now several laboratory tests show that the products are free of contaminants and impurities without the use of radiation - a process that is common within the industry.
DanCann Pharma’s biomaterial is produced based on best practices from the pharmaceutical industry in combination with advanced environmentally controlled cultivation technology and vertical cultivation. The genetics are cultivated in boxes on several floors without the use of soil or other media but with a specially developed system that adds the necessary fertilizers and nutrients. The automated cultivation processes and minimized external product contact have created significant results so far.
Morten Martinsen, Business Developer & Co-founder at DanCann Pharma, comments: "We have received the analysis of the purity of our biomaterial, and we are very pleased. The results are very unique in the industry, where it has not previously been possible to achieve a similar purity without the use of radiation, and it gives us a huge boost in the continued work in our production facilities in Biotech Pharm1."
QNTM Labs is an advanced analytical laboratory providing research, development, and regulatory compliance services for pharmaceutical companies. QNTM Labs have conducted tests and chemical analyses of DanCann Pharma’s biomaterial in the company’s exclusive test environment.
Justin Ihnken, CEO of QNTM Labs, comments on the test results: "QNTM Labs has found these results to satisfy the rigorous Danish regulatory requirements, and upon concluding analysis, it was evident that the quantification levels of bacteria and microbiological organisms in DanCann Pharma’s samples were well below the allowable detection limits. We seek to uphold the highest level of quality standards in pharmaceutical lab testing globally, and DanCann Pharma’s recent laboratory results are a testament to their approach to quality cultivation and production of medical cannabis."
By being able to avoid the irradiation step entirely, DanCann Pharma is able to conserve and preserve the valuable ingredients and active components found within the flower - and several markets have introduced a ban on the sale of irradiated products, including states in Germany.
For more information:
DanCann Pharma
info@dancann.com
www.dancann.com